Search the Newsreel

CGON (CGON) insider Ambaw Bellete plans 25,000-share stock sale via broker

CG Oncology, Inc. (CGON) insider Ambaw Bellete has filed a Form 144 notice to sell up to 25,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,837,500.00. The shares, acquired via a stock option exercise, are …

Price to earnings forward of CG Oncology, Inc. – NASDAQ:CGON

This article provides the "Price to earnings forward" metric for CG Oncology, Inc. (NASDAQ: CGON) on TradingView. It appears to be a financial data point displayed within a larger financial analysis platform. The specific value and change percentage are indicated as data fields.

CG Oncology (CGON) to Post Earnings on Friday

CGON|CG Oncology Inc|Price:69.180|Chg%:-3.440

This article provides a comprehensive stock analysis of CG Oncology Inc (CGON) from TradingKey. The company's fundamentals are considered healthy with high growth potential, and its valuation is deemed fairly valued within the Biotechnology & Medical Research industry. Analysts have given a "Buy" rating …

What CG Oncology (CGON)'s Pivotal BOND-003 Phase 3 Data Means For Shareholders

CG Oncology recently published pivotal Phase 3 BOND-003 data in The Lancet Oncology, showing that its monotherapy, cretostimogene grenadenorepvec, achieved significant complete responses with durable outcomes and a favorable safety profile for high-risk bladder cancer. This positive report strengthens the company's investment narrative by …

Law firm investigates CG Oncology officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating officers and directors of CG Oncology, Inc. for potential breaches of fiduciary duties through self-dealing. This probe could result in damages for shareholders and corporate governance reforms, and long-term shareholders are encouraged to contact the law firm.

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled …

CGON (CGON) insider files to sell 4,303 shares after option exercise

An insider at CG Oncology, Inc. (CGON) has filed a Form 144 notice to sell 4,303 common shares after exercising stock options on July 29, 2026. This sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also details …

CGON (CGON) insider Ambaw Bellete files to sell 50,000 shares

Ambaw Bellete, an insider at CG Oncology, Inc. (CGON), has filed a Form 144 indicating an intention to sell 50,000 shares of common stock. This planned sale, valued at approximately $3.6 million, is scheduled for on or after July 28, 2026, and is connected …

LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $108

LifeSci Capital has reiterated its Buy rating on CG Oncology (CGON.US) and maintained its target price of $108. This indicates continued confidence from the firm in the company's prospects.

CG Oncology Inc. (CGON) Experiences Modest Pullback as Shares Trade Near Support - Cash Secured Put

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

DALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec monotherapy in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with …

About 81% of BOND-003 patients maintained their bladders at 24 months

CG Oncology (NASDAQ: CGON) announced the publication of pivotal Phase 3 BOND-003 Cohort C study results in The Lancet Oncology. The study evaluated cretostimogene grenadenorepvec monotherapy for high-risk, BCG-unresponsive non-muscle invasive bladder cancer and met its primary endpoint with a 75.5% complete response rate. …

BlackRock, Inc. (CGON) discloses 6.8% beneficial ownership in CG Oncology

BlackRock, Inc. has filed an amended Schedule 13G disclosing a 6.8% beneficial ownership in CG Oncology (CGON), amounting to 6,023,696 shares of common stock. BlackRock holds sole voting power over 5,914,671 shares and sole dispositive power over all 6,023,696 shares. The filing specifies that …

CGON (CGON) filer discloses 50,000-share sale plan and recent stock sales

An affiliate of CG Oncology (CGON), Ambaw Bellete, has filed a notice to sell 50,000 shares of common stock, valued at $3,627,995.00, through a stock option exercise on July 27, 2026. The filing also reports prior sales by the same individual, including 50,000 shares …

CG Oncology Inc (CGON) Income Statement

This article presents the quarterly and annual income statements for CG Oncology Inc (CGON), offering detailed financial data such as revenue, operating expenses, and net income. It covers fiscal years from FY2022Q4 to FY2026Q1, providing insights into the company's financial performance and operational efficiency. …

CG Oncology Inc (CGON) Institutional Confidence

The article analyzes the institutional confidence score for CG Oncology Inc (CGON), which is currently 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional shareholding decreased by 9.96% quarter-over-quarter, with Bill Nygren | OAKMX identified as the largest institutional shareholder despite …

CGON Cash Flow Statement

This article provides a detailed quarterly and annual cash flow statement for CG Oncology Inc (CGON), allowing users to assess the company's financial health. It includes operating, investing, and financing cash flow data with year-over-year percentage changes, along with an FAQ section explaining key …

CG Oncology Inc (CGON) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for CG Oncology Inc (CGON), detailing its financial performance by business segment and regional contributions. The data indicates that specific detailed financial figures for business segments are not yet disclosed by the company. However, regional revenue shows a …

CGON (CGON) insider files to sell 50,000 shares after option exercise

An insider at CG Oncology, Inc. (CGON) has filed a Form 144 to sell 50,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ on July 23, 2026, with an aggregate market value of $3,588,620.00. These shares were acquired via a stock option …

CG Oncology Inc (CGON) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of CG Oncology Inc (CGON), noting its current valuation score of 9.05, placing it 64th out of 386 in the Biotechnology & Medical Research industry. It details the company's P/E ratio, indicating it is -29.59, and mentions that …

CG Oncology Stock: Priced To Perfection On Future Pipeline Success (NASDAQ:CGON)

CG Oncology (CGON) is currently rated Hold, primarily because its $6.3 billion valuation appears to fully price in the anticipated success of its lead asset, cretostimogene grenadenorepvec, and future pipeline expansions. While cretostimogene shows strong promise with an 75-85% Complete Response rate in BCG-unresponsive …

CG Oncology director Leonard Post disposes of 1,000 shares for $71,170

CG Oncology director Leonard E. Post sold 1,000 common shares on July 15 for $71.17 each, reducing his direct stake to zero. Concurrently, Post exercised 1,000 director stock options at $0.60 on the same day, acquiring 1,000 shares, and now holds 105,077 director stock …

CG Oncology (CGON) director sells 1,000 shares at $71.17

CG Oncology, Inc. director Leonard E. Post exercised stock options for 1,000 shares at $0.60 per share and subsequently sold all 1,000 shares at $71.17 per share on July 15, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on March …

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

ANI Pharmaceuticals (Nasdaq: ANIP) announced its intent to appeal the trial court's denial of its post-trial motions for a new trial and judgment as a matter of law in its dispute with CG Oncology. The company plans to appeal to the Delaware Supreme Court …

Form 144 CG ONCOLOGY For: 15 July By Investing.com

This article announces the filing of Form 144 for CG Oncology on July 15. Form 144 is a notice of the intent to sell restricted securities. The brief article, published by Investing.com, indicates this filing without providing further details on the transaction or its …

[144] CG Oncology, Inc. SEC Filing

This SEC filing for CG Oncology, Inc. (CGON) outlines a Form 144 Notice of Proposed Sale of Securities. The filing details the sale of 52,438 shares of common stock with an aggregate market value of $3,816,007.65, acquired through a stock option exercise, by an …

How CG Oncology’s Phase II Bladder Cancer Data and 2026 BLA Timeline Will Impact CGON Investors

CG Oncology has released positive Phase II trial data for its lead bladder cancer therapy, cretostimogene grenadenorepvec, and plans to complete a Biologics License Application (BLA) by Q4 2026 for high-risk BCG-unresponsive non-muscle invasive bladder cancer. This progress strengthens the investment case for CGON, …